Skip to main content

Table 3 Logistic regression models for grade 3 and higher acute non-hematologic toxicities, late non-hematologic toxicities, and hospitalizations for patients living with HIV undergoing definitive chemoradiation for anal carcinoma

From: The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study

  Acute ≥ G3 non-hematologic toxicities Late ≥ G3 non-hematologic toxicities Hospitalization
Univariate Model Adjusted Model Univariate Model Adjusted Model Univariate Model Adjusted Model
OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value
Age at diagnosis
  < 40 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
 40–59 0.40 (0.12–1.39) 0.15 0.44 (0.12–1.62) 0.22 0.46 (0.09–2.32) 0.34 0.43 (0.08–2.26) 0.32 0.60 (0.18–1.95) 0.40 0.49 (0.13–1.88) 0.30
 60+ 0.55 (0.15–2.01) 0.37 0.58 (0.15–2.26) 0.43 1.30 (0.25–6.68) 0.75 1.42 (0.27–7.60) 0.68 0.58 (0.17–1.99) 0.38 0.61 (0.15–2.50) 0.49
Race/Ethnicity
 Caucasian 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
 African American 0.63 (0.35–1.14) 0.12 0.63 (0.34–1.18) 0.15 1.22 (0.48–3.11) 0.67 1.49 (0.57–3.94) 0.42 1.71 (0.94–3.11) 0.08 1.80 (0.90–3.59) 0.10
 Hispanic 1.14 (0.42–3.11) 0.79 1.18 (0.41–3.43) 0.76 1.82 (0.45–7.28) 0.40 1.87 (0.45–7.81) 0.39 1.00 (0.35–2.88) 0.99 0.97 (0.29–3.22) 0.96
 Other/ Unknown 0.69 (0.22–2.11) 0.51 0.77 (0.14–2.48) 0.66 3.64 (0.98–13.56) 0.05 4.62 (1.17–18.22) 0.03 1.11 (0.35–3.55) 0.86 2.66 (0.68–10.31) 0.16
HIV Medication
 No Protease Inhibitor 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
 Protease Inhibitor 1.38 (0.77–2.46) 0.28 1.34 (0.72–2.48) 0.36 1.27 (0.51–3.16) 0.61 1.55 (0.59–4.07) 0.37 2.44 (1.27–4.65) < 0.01 2.17 (1.04–4.56) 0.04
Year HIV Diagnosed
  < 2000 1.00 Ref    1.00 Ref    1.00 Ref   
 2000–2009 1.05 (0.58–1.91) 0.87    1.44 (0.59–3.49) 0.42    0.81 (0.43–1.51) 0.51   
 2010–2016 1.28 (0.44–3.72) 0.65    2.12 (0.54–8.36) 0.28    1.38 (0.48–4.03) 0.55   
Smoker
 Never 1.00 Ref    1.00 Ref    1.00 Ref 1.00 Ref
 Current 1.06 (0.56–2.00) 0.87    0.68 (0.24–1.89) 0.46    1.41 (0.71–2.80) 0.33 1.74 (0.76–4.01) 0.19
 Former 0.90 (0.40–2.05) 0.80    1.87 (0.61–5.67) 0.27    2.83 (1.20–6.67) 0.02 3.21 (1.19–8.66) 0.02
 Unknown 0.09 (0.01–0.75) 0.03    1.40 (0.25–7.76) 0.70    0.46 (0.09–2.32) 0.35 0.63 (0.11–3.62) 0.61
Stage
 I 1.00 Ref    1.00 Ref    1.00 Ref 1.00 Ref
 II 1.37 (0.64–2.95) 0.41    2.77 (0.60–12.76) 0.19    1.32 (0.57–3.03) 0.52 1.14 (0.45–2.89) 0.78
 IIIA 0.70 (0.21–2.29) 0.55    2.13 (0.27–16.48) 0.47    1.66 (0.50–5.47) 0.41 1.20 (0.32–4.52) 0.79
 IIIB 2.14 (0.89–5.15) 0.09    2.43 (0.46–12.81) 0.30    2.60 (1.03–6.54) 0.04 2.14 (0.76–6.00) 0.15
 IV 0.56 (0.10–3.28) 0.52    6.80 (0.77–59.75) 0.08    15.6 (1.66–146) 0.02 16.35 (1.47–181.9) 0.02
Nadir CD4 during Radiation
  ≤ 200 1.00 Ref    1.00 Ref    1.00 Ref 1.00 Ref
  > 200 0.59 (0.31–1.13) 0.11    0.77 (0.29–2.01) 0.59    0.48 (0.24–0.95) 0.03 0.53 (0.24–1.20) 0.13
 Unknown 0.64 (.034–1.22) 0.18    0.49 (0.17–1.43) 0.19    0.40 (0.20–0.80) < 0.01 0.38 (0.17–0.83) 0.02
BMI
  < 25 1.00 Ref 1.00 Ref 1.00 Ref    1.00 Ref 1.00 Ref
 25–30 0.92 (0.51–1.67) 0.79 1.00 (0.54–1.86) 0.99 0.54 (0.22–1.36) 0.19    1.07 (0.58–1.95) 0.84 0.85 (0.43–1.70) 0.65
 ≥ 30 0.37 (0.14–0.95) 0.04 0.43 (0.16–1.14) 0.09 – –    0.28 (0.09–0.86) 0.03 0.27 (0.07–0.95) 0.04
 Unknown 0.95 (0.26–3.46) 0.94 0.88 (0.22–3.53) 0.85 0.55 (0.07–4.60) 0.58    0.62 (0.15–2.54) 0.51 0.75 (0.15–3.68) 0.72
Radiation Modality
 2D + 3D 1.00 Ref 1.00 Ref 1.00 Ref    1.00 Ref   
 IMRT 0.58 (0.31–1.12) 0.10 0.67 (0.34–1.33) 0.26 0.78 (0.29–2.09) 0.62    0.72 (0.37–1.38) 0.32   
 Unknown 0.45 (0.23–0.88) 0.02 0.49 (0.24–0.97) 0.04 0.98 (0.37–2.56) 0.96    0.64 (0.32–1.25) 0.19   
Chemotherapy Regimen
 5FU + mitomycin C 1.00 Ref    1.00 Ref    1.00 Ref   
 5FU + cisplatin 0.62 (0.25–1.49) 0.28    1.60 (0.49–5.21) 0.44    1.09 (0.46–2.61) 0.84   
 Other 0.97 (0.46–2.04) 0.93    1.43 (0.49–4.17) 0.51    0.57 (0.25–1.32) 0.19   
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us